CAS 生命科学数据
开展全新的生命科学发现时，完整且关联的数据是成功的关键。 借助世界上最值得信赖、最可靠的科学信息来源 CAS 内容合集™，深入研究疾病、靶点和新型分子之间的关系。
联系我们
开展全新的生命科学发现时，完整且关联的数据是成功的关键。 借助世界上最值得信赖、最可靠的科学信息来源 CAS 内容合集™，深入研究疾病、靶点和新型分子之间的关系。
We hope you’ve been enjoying the preview of CAS life sciences content and capabilities in CAS SciFinder®, which will end on June 1, 2024. These capabilities and many more are now available through the CAS BioFinder Discovery PlatformTM, which includes CAS BioFinder™, our newest solution to serve drug discovery scientists.
The CAS BioFinder Discovery Platform offers seamless integration with the capabilities you’ve seen in CAS SciFinder, such as sequence searches and bioactivity tables linked to reference documents and assay details. In addition, CAS BioFinder features embedded analytical and predictive models to help you explore the predicted behavior of novel molecules. The full platform also includes CAS APIs to directly access our human-curated bioactivity and biomarker data.
With this new platform, you can dive deeper to answer key drug discovery questions with the trusted, harmonized, and connected CAS content you depend on combined with analytical and predictive models directly accessible from your search results.
- What scaffolds and molecules are associated with my disease of interest?
- What molecules are known or likely to interact with my target of interest?
- What targets are known or likely to interact with my molecules of interest?
- What biomarkers are relevant to my disease of interest?
关于生命科学数据的更多信息
为生命科学建立权威结构的挑战和机遇
CAS 数据专家 Nicole Stobart、Jeff Wilson 博士和 Mark Schmidt 研究了创建新的权威结构来组织生命科学数据的困难和重要性。
药物发现过程中序列分析的挑战与机遇
Jefferson Parker，博士 NullSet Informatics Solutions 的 Jefferson Parker 博士分享了序列分析的重要性、人工智能技术如何改进序列分析以及仍然存在的关键问题。
构效关系 (SAR) 研究过程中的挑战与机遇
Ben R. Taft，博士 通过 Nova Therapeutics，我们探讨了 SAR 研究的变化、新技术对其产生的影响以及如何解决当前的瓶颈问题。
发现“不可成药”靶点新药的挑战与机遇
来自 Abilita Therapeutics 的 Mauro Mileni 博士和 Chris Roth 博士讨论了科学家如何利用正确的技术来填补创新药物管道。
药物发现蛋白功能预测的挑战与机遇
爱荷华州立大学副教授 Iddo Friedberg 博士讨论了当前蛋白质功能预测模型的性能等。